Keyword: Alnylam Pharmaceuticals

Intellia Therapeutics is developing a CRISPR-based treatment to edit the mutation that causes transthyretin amyloidosis.

Alnylam says it will have to wait for the final results of a phase 3 trial of acute hepatic porphyria drug givosiran before filing.

Akcea has its first FDA approval for hATTR therapy Tegsedi but will be burdened with a black box warning as it chases rival Alnylam.

The readout linked the ALAS1-targeted RNAi to a drop in urinary ALA, a biomarker Alnylam and the FDA think may predict clinical benefit. 

Boehringer’s Corsico jumps to head dev at GSK; Kite’s Polverino takes CSO role at Zymeworks; and Kymera taps former Alnylam executive as CMO.

Jared Gollob, M.D., is joining Kymera Therapeutics, a startup focused on protein degradation.

Pfizer’s ATTR drug tafamidis has hit the mark in a phase 3 trial, setting up regulatory filings and a challenge to rivals Alnylam and Ionis/Akcea.

Eidos' $106 million IPO comes on the heels of a $64 million series B and will support phase 2 and phase 3 trials of its TTR amyloidosis drug.

BOSTON—We caught up John Maraganore at this year's meeting to ask him about drug pricing, immigration and the culture at biotech versus pharma companies.

After a turbulent year, Prothena is reorganizing to rally its resources around what remains in its neuroscience pipeline.